Compare ESCA & SLGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ESCA | SLGL |
|---|---|---|
| Founded | 1922 | 1997 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Recreational Games/Products/Toys | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 257.2M | 247.1M |
| IPO Year | 1995 | 2016 |
| Metric | ESCA | SLGL |
|---|---|---|
| Price | $18.63 | $72.87 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $110.00 |
| AVG Volume (30 Days) | 23.1K | ★ 32.6K |
| Earning Date | 04-30-2026 | 05-22-2026 |
| Dividend Yield | ★ 3.50% | N/A |
| EPS Growth | ★ 6.45 | N/A |
| EPS | ★ 0.32 | N/A |
| Revenue | ★ $180,541,000.00 | N/A |
| Revenue This Year | $4.15 | N/A |
| Revenue Next Year | N/A | $223.84 |
| P/E Ratio | $58.22 | ★ N/A |
| Revenue Growth | ★ 2.71 | N/A |
| 52 Week Low | $11.41 | $6.96 |
| 52 Week High | $21.32 | $97.97 |
| Indicator | ESCA | SLGL |
|---|---|---|
| Relative Strength Index (RSI) | 49.40 | 48.36 |
| Support Level | $17.33 | $66.40 |
| Resistance Level | $18.72 | $81.64 |
| Average True Range (ATR) | 0.57 | 6.00 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 43.19 | 40.95 |
Escalade Inc manufactures and distributes sporting goods for a varied range of activities. These sports include archery, table tennis, basketball goals, trampoline, play systems, fitness, game tables like hockey and soccer, billiards, darting, and other outdoor games. These products are sold under the brand names like Goalrilla, Goalsetter, Woodplay, Silverback, Nodor, Rage, Child Life, among others. The geographic segments in which the company operates are the United States, Canada, Australia, and Other regions.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted.